Endocrinol Metab.  2024 Feb;39(1):12-22. 10.3803/EnM.2024.1942.

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

• Jakubowska A
• Roux CWl
• Viljoen A

• KMID: 2552791
• DOI: http://doi.org/10.3803/EnM.2024.1942

Abstract

Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose- dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood pressure, inflammation, and hepatic steatosis. The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions.

Keyword

Triple agonists; Triagonists; Glucagon-like peptide 1; Gastric inhibitory polypeptide; Glucagon; Obesity; Weight loss; Retatrutide; Co-agonist

Figure

• 

  Fig. 1. Action of glucagon in humans.

• 

  Fig. 2. Action of glucose-dependent insulinotropic polypeptide (GIP) in humans.

• 

  Fig. 3. Action of glucagon-like peptide-1 (GLP-1) in humans.

Reference

1. Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019; 15:288–98.

2. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377:13–27.

3. Akalestou E, Miras AD, Rutter GA, le Roux CW. Mechanisms of weight loss after obesity surgery. Endocr Rev. 2022; 43:19–34.

4. Lim R, Beekley A, Johnson DC, Davis KA. Early and late complications of bariatric operation. Trauma Surg Acute Care Open. 2018; 3:e000219.

5. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023; 58:101882.

6. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017; 127:4217–27.

7. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373:11–22.

8. Nogueiras R, Nauck MA, Tschop MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023; 5:933–44.

9. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387:205–16.

10. Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023; 402:720–30.

11. Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023; 79:1557–65.

12. Scheen AJ, Lefebvre PJ. Glucagon, from past to present: a century of intensive research and controversies. Lancet Diabetes Endocrinol. 2023; 11:129–38.

13. Guzman CB, Zhang XM, Liu R, Regev A, Shankar S, Garhyan P, et al. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19:1521–8.

14. Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017; 97:721–66.

15. Alberti KG, Johnston DG, Gill A, Barnes AJ, Orskov H. Hormonal regulation of ketone-body metabolism in man. Biochem Soc Symp. 1978; 43:163–82.

16. Tschop M, Nogueiras R, Ahren B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023; 66:1796–808.

17. Inagaki N, Seino Y, Takeda J, Yano H, Yamada Y, Bell GI, et al. Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene. Mol Endocrinol. 1989; 3:1014–21.

18. El K, Campbell JE. The role of GIP in α-cells and glucagon secretion. Peptides. 2020; 125:170213.

19. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010; 1:8–23.

20. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993; 133:2861–70.

21. Turner DS, Etheridge L, Jones J, Marks V, Meldrum B, Bloom SR, et al. The effect of the intestinal polypeptides, IRP and GIP, on insulin release and glucose tolerance in the baboon. Clin Endocrinol (Oxf). 1974; 3:489–93.

22. Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013; 56:965–72.

23. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology. 1978; 103:610–5.

24. Muller TD, Clemmensen C, Finan B, DiMarchi RD, Tschop MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev. 2018; 70:712–46.

25. Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 2019; 30:987–96.

26. Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, Vilsboll T, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion: a review. Int J Mol Sci. 2019; 20:4092.

27. Adriaenssens A, Broichhagen J, de Bray A, Ast J, Hasib A, Jones B, et al. Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding. JCI Insight. 2023; 8:e164921.

28. Drucker DJ, Brubaker PL. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci U S A. 1989; 86:3953–7.

29. Graaf Cd, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016; 68:954–1013.

30. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987; 84:3434–8.

31. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018; 27:740–56.

32. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes. 2007; 56:1671–9.

33. Muller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30:72–130.

34. Mojsov S. Structural requirements for biological activity of glucagon-like peptide-I. Int J Pept Protein Res. 1992; 40:333–43.

35. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993; 268:19650–5.

36. Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012; 59:464–71.

37. Viljoen A, Bain SC. Glucagon-like peptide 1 therapy: from discovery to type 2 diabetes and beyond. Endocrinol Metab (Seoul). 2023; 38:25–33.

38. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023; 389:2221–32.

39. Gragnano F, De Sio V, Calabro P. FLOW trial stopped early due to evidence of renal protection with semaglutide. Eur Heart J Cardiovasc Pharmacother. 2024; 10:7–9.

40. Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2013; 3:241–51.

41. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009; 58:2258–66.

42. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009; 5:749–57.

43. Corbin KD, Carnero EA, Allerton TD, Tillner J, Bock CP, Luyet PP, et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity (Silver Spring). 2023; 31:350–62.

44. Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018; 391:2607–18.

45. Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, et al. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, phase 1 study. Br J Clin Pharmacol. 2018; 84:2325–35.

46. Parker VE, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, et al. Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist. J Clin Endocrinol Metab. 2020; 105:dgz047.

47. Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021; 44:1433–42.

48. Bluher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024; 67:470–82.

49. Busko M. Survodutide impresses in phase 2 weight-loss trial [Internet]. New York: Medscape;2023. [cited 2024 Jan 31]. Available from: https://www.medscape.com/viewarticle/993928?form=fpf.

50. Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013; 5:209ra151.

51. Gault VA, Kerr BD, Harriott P, Flatt PR. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin Sci (Lond). 2011; 121:107–17.

52. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018; 18:3–14.

53. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385:503–15.

54. Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021; 398:583–98.

55. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022; 327:534–45.

56. Heerspink HJ, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10:774–85.

57. Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10:634–44.

58. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015; 21:27–36.

59. Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, et al. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metab. 2017; 6:440–6.

60. Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjollund KR, He Y, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022; 63:101533.

61. Bossart M, Wagner M, Elvert R, Evers A, Hubschle T, Kloeckener T, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab. 2022; 34:59–74.

62. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022; 34:1234–47.

63. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022; 400:1869–81.

64. Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023; 389:514–26.

65. van Rijswijk AS, van Olst N, Schats W, van der Peet DL, van de Laar AW. What is weight loss after bariatric surgery expressed in percentage total weight loss (%TWL)?: a systematic review. Obes Surg. 2021; 31:3833–47.

66. Gossmann M, Butsch WS, Jastreboff AM. Treating the chronic disease of obesity. Med Clin North Am. 2021; 105:983–1016.

67. Sanyal AJ. Retatrutide NAFLD: phase 2 trial results in subset of patients with obesity and NAFLD. In : American Diabetes Association’s 83rd Scientific Sessions; 2023 Jun 23-26; San Diego, CA.

68. Kim JA, Lee S, Lee SH, Jung SY, Kim YH, Choi IY, et al. Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models. Diabetes. 2018; 67(Supplement 1):1107–P.

69. Choi IY, Lee JS, Kim JK, Lee SH, Kim YH, Park YJ, et al. Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211). In : American Diabetes Association’s 77th Scientific Sessions; 2017 Jun 9-13; San Diego, CA.

70. Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, et al. A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes. Br J Pharmacol. 2022; 179:4360–77.

71. Iacobucci G. Diabetes: doctors are told not to start new patients on GLP-1 agonists because of shortages. BMJ. 2023; 382:p2019.

72. Dent R, McPherson R, Harper ME. Factors affecting weight loss variability in obesity. Metabolism. 2020; 113:154388.

73. Fruhbeck G, Kiortsis DN, Catalan V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol. 2018; 6:164–6.